Heparin Reversal for Coronary Artery Perforation
Catheterization and Cardiovascular Interventions · 2025-02 · 105 (2) · 464-474
DOI: 10.1002/ccd.31339 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, published online on 2024-12-10. Written by Yuichi Sawayama and 10 co-authors. Institution: Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan. Major MEDLINE topics: Percutaneous Coronary Intervention, Heparin, Coronary Vessels, Anticoagulants. Cited 3 times so far (Crossref); 18 references.
Abstract (original language)
Background
Reversing heparin when managing coronary artery perforation (CAP) during percutaneous coronary intervention (PCI) can provide hemostasis but may cause coronary thrombosis if a device is still present in a coronary artery.
Aims
To assess the impact of heparin reversal while an intracoronary artery device is in place for CAP.
Methods
This study analyzed CAP cases during PCI from January 2006 to October 2023. Patients were grouped according to implementing heparin reversal while an intracoronary artery device was in place. The safety outcome was coronary thrombosis after CAP. The efficacy outcomes were successful hemostasis and death from any cause.
Results
CAP occurred in 368 of 22,368 cases (1.6%). Patients who had heparin reversal with a device in place comprised 211 (57%). Among these, coronary thrombosis occurred in 16 (7.6%). An activated clotting time (ACT) 〈150 seconds was significantly correlated with coronary thrombosis. Heparin reversal with a device in place was significantly associated with successful hemostasis (heparin reversal 91% vs. no heparin reversal 73%; adjusted odds ratio 2.78; 95% confidence interval 1.27−6.13; p = 0.011), but was not different for death from any cause (heparin reversal 4.3% vs. no heparin reversal 5.7%; adjusted odds ratio 0.97; 95% confidence interval 0.28−3.43; p = 0.964).
Conclusion
Heparin reversal with a device in place was associated with an increased risk of coronary thrombosis when ACT was less than 150 seconds. While it may not have a substantial association with a reduced risk of mortality, it offers an advantage in achieving successful hemostasis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan.
ORCID profiles: Yuichi Sawayama, Narumi Taninobu, Akihiro Ikuta, Yasushi Fuku
Cite
APA
Sawayama, Y., Sasaki, K., Taninobu, N., Ikuta, A., Osakada, K., Kubo, S., Tada, T., Fuku, Y., Tanaka, H., Nakagawa, Y., & Kadota, K. (2025). Heparin Reversal for Coronary Artery Perforation. Catheterization and Cardiovascular Interventions, 105(2), 464-474. https://doi.org/10.1002/ccd.31339
Vancouver
Sawayama Y, Sasaki K, Taninobu N, Ikuta A, Osakada K, Kubo S, et al. Heparin Reversal for Coronary Artery Perforation. Catheterization and Cardiovascular Interventions. 2025;105(2):464-474. doi:10.1002/ccd.31339
BibTeX
@article{Sawayama2025,
author = {Sawayama, Yuichi and Sasaki, Kenta and Taninobu, Narumi and Ikuta, Akihiro and Osakada, Kohei and Kubo, Shunsuke and Tada, Takeshi and Fuku, Yasushi and Tanaka, Hiroyuki and Nakagawa, Yoshihisa and Kadota, Kazushige},
title = {Heparin Reversal for Coronary Artery Perforation},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
volume = {105},
number = {2},
pages = {464--474},
doi = {10.1002/ccd.31339}
}
EUVIMED